Impact of gemcitabine on the survival of patients with stage IV pancreatic cancer

Pancreas

Volumn 34, Issue 3, 2007, Pages 335-339

  Fujino, Yasuhiro ^a   Ueda, Takashi ^a   Kamigaki, Takashi ^a   Takase, Shiro ^a   Ajiki, Tetsuo ^a   Kamoda, Yasuhisa ^a   Matsumoto, Ippei ^a   Yasuda, Takeo ^a   Kuroda, Yoshikazu ^a  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Chemotherapy; Gemcitabine; Pancreatic cancer; Stage IV

Indexed keywords

GEMCITABINE;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER INVASION; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTIVARIATE ANALYSIS; PANCREAS CANCER; PRIORITY JOURNAL; PROGNOSIS; SEX DIFFERENCE; STATISTICAL ANALYSIS; TUMOR LOCALIZATION; TUMOR VOLUME;

AGED; ANTIMETABOLITES, ANTINEOPLASTIC; DEOXYCYTIDINE; FEMALE; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM STAGING; PANCREATIC NEOPLASMS; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 34247164759     PISSN: 08853177     EISSN: None     Source Type: Journal    
DOI: 10.1097/MPA.0b013e31802638     Document Type: Article

References (20)

1. Warshaw AL, Castillo CF. Pancreatic carcinoma. N Engl J Med. 1992;326:455-465.
2. Niederhuber JE, Brennan MF, Menck HR. The national cancer data base report on pancreatic cancer. Cancer. 1995;76:1671-1677.
3. Cameron JL, Crist DW, Sitzmann JV, et al. Factors influencing survival after pancreatico-duodenectomy for pancreatic cancer. Am J Surg. 1991;161:120-125.
4. Conlon KC, Klimstra DS, Brennan MF. Long-term survival after curative resection for pancreatic ductal adenocarcinoma. Ann Surg. 1996;223:273-279.
5. Imamura M, Doi R. Treatment of locally advanced pancreatic cancer: should we resect when respectable? Pancreas. 2004;28:293-296.
6. Matsuno S, Egawa S, Fukuyama S, et al. Pancreatic cancer registry in Japan: 20 years of experience. Pancreas. 2004;28:219-230.
7. Pancreatic Section, British Society of GastroenterologyPancreatic Society of Great Britain and IrelandAssociation of Upper Gastrointestinal Surgeons of Great Britain and IrelandRoyal College of Pathologists; Special Interest Group for Gastro-Intestinal Radiology. Guidelines for the management of patients with pancreatic cancer periampullary and ampullary carcinomas. Gut. 2005;54:1-16.
8. Fujino Y, Suzuki Y, Kamigaki T, et al. Evaluation of gastroenteric bypass for unresectable pancreatic cancer. Hepatogastroenterology. 2001;48:563-567.
9. Kalser MH, Ellenberg SS. Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg. 1985;120:899-903.
10. Neoptolemos JP, Stocken DD, Friess H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med. 2004;350:1200-1210.
11. Burris BHA III, Moore MJ, Anderson J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15:2403-2413.
12. Japan Pancreas Society. Classification of Pancreatic Carcinoma, 1st English ed. Tokyo: Kanehara; 1996.
13. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5:649-655.
14. Rothenberg ML, Moore MJ, Cripps MC, et al. A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. Ann Oncol. 1996;7:347-353.
15. Maisey NR, Norman AR, Hill A, et al. CA19-9 as a prognostic factor in inoperable pancreatic cancer: the implication for clinical trials. Br J Cancer. 2005;93:740-743.
16. Ko AH, Hwang J, Venook AP, et al. Serum CA 19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic cancer. Br J Surg. 2005;93:195-199.
17. Nakao A, Takeda S, Sakai M, et al. Extended radical resection versus standard resection for pancreatic cancer: the rationale for extended radical resection. Pancreas. 2004;28:289-292.
18. Nagakawa T, Nagamori M, Futakami F, et al. Results of extensive surgery for pancreatic carcinoma. Cancer. 1996;77:640-645.
19. Neoptolemos JP, Stocken DD, Friess H, et al. European Study Group for Pancreatic Cancer. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med. 2004;350:1200-1210.
20. Smeenk HG, Incrocci L, Kazemier G, et al. Adjuvant 5-FU-based chemoradiotherapy for patients undergoing R-1/R-2 resections for pancreatic cancer. Dig Surg. 2005;22:321-328.